Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | PKM | P14618 | 5/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | RGS12 | O14924 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074791 | 1.00 | KMT2A (0.57) | KMT2APKMMAPK1POLBLMNA | |
| SCHEMBL4074794 | 1.00 | KMT2A (0.57) | KMT2APKMMAPK1POLBLMNA | |
| SCHEMBL7963939 | 0.93 | IGF1R (0.53) | KMT2APKMMAPK1POLBLMNA | |
| SCHEMBL7963934 | 0.93 | IGF1R (0.53) | KMT2APKMMAPK1POLBLMNA | |
| SCHEMBL7963935 | 0.93 | IGF1R (0.53) | KMT2APKMMAPK1POLBLMNA | |
| SCHEMBL7962829 | 0.89 | KMT2A (0.61) | KMT2APKMMAPK1POLBLMNA | |
| SCHEMBL7962831 | 0.89 | KMT2A (0.61) | KMT2APKMMAPK1POLBLMNA | |
| SCHEMBL7962827 | 0.89 | KMT2A (0.61) | KMT2APKMMAPK1POLBLMNA | |
| SCHEMBL5363714 | 0.85 | PKM (0.60) | KMT2APKMMAPK1POLBLMNA | |
| SCHEMBL5363709 | 0.85 | PKM (0.60) | KMT2APKMMAPK1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5789427-A | ANTITUMOR, ANTICANCER AGENTS | SUGEN, INC. (US) | 1998-08-04 | — | — | US | claimed |
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7217737-B2 | Method and compositions for inhibiting cell proliferative disorders | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-05-15 | — | — | US | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| US-20040242684-A1 | Method and compositions for inhibiting cell proliferative disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2004-12-02 | — | — | US | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
| US-6596878-B2 | Protein kinase inhibitor compositio; used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR. | YISSUM RESEARCH & DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY (IL) | 2003-07-22 | — | — | US | disclosed |
| US-6225346-B1 | FOR THERAPY AND PROPHYLAXIS OF CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS ASSOCIATED WITH PARTICULAR TYROSINE KINASES BY INHIBITING ONE OR MORE ABNORMAL TYROSINE KINASE ACTIVITIES | SUGEN, INC. | 2001-05-01 | — | — | US | disclosed |
| US-5935993-A | TYROSINE KINASE INHIBITORS; TREATMENT OF CELL GROWTH, CELL DIFFERENTIATION DISORDERS | SUGEN, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| US-5891917-A | MODULATING TYROSINE SIGNAL TRANSDUCTION TO PREVENT AND TREAT CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS ASSOCIATED WITH PARTICULAR TYROSINE KINASES BY INHIBITING ONE OR MORE ABNORMAL TYROSINE KINASE ACTIVITIES | SUGEN, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5773476-A | KINASE INHIBITORS | SUGEN, INC. (IL) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242684-A1 | Method and compositions for inhibiting cell proliferative disorders | ERBB2, EGFR, MKI67 | KMT2A 1810/4885PKM 1500/4885MAPK1 217/4885 |
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | KMT2A 2506/4885PKM 1478/4885MAPK1 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.